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Introduction
Gatifloxacin, a recently introduced fluoroquino-
lone, possesses good activity against a wide range of 
gram-positive and gram-negative pathogens, atypical 
organisms and some anaerobes1. It is commonly in-
dicated for the treatment of acute bacterial sinusitis, 
chronic bronchitis, pneumonia, urinary tract infec-
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Abstract
The pharmacokinetics of intravenously administered gatifloxacin, upon concomitant administration with meloxicam 
was investigated in buffalo calves. Meloxicam was administered subcutaneously (0.5 mg.kg-1) immediately followed by 
intravenous administration of Gatifloxacin (4 mg.kg-1). The concentration of gatifloxacin was estimated in plasma by 
microbiological assay. Pharmacokinetic parameters were calculated and appropriate dosage schedule was computed. The 
therapeutic plasma drug concentration was maintained up to 12 h. Gatifloxacin was rapidly distributed from blood to 
tissue compartment, which was evident from the high values of distribution rate constant, α1 (11.9 ± 0.52 h-1) and the ratio of rate constant of transfer of drug from central to peripheral compartments and vice versa, K12/K21 (3.05 ± 0.36) and K13/K31 (2.04 ± 0.12). The area under the plasma drug concentration-time curve and apparent volume of distribution were 12.0 ± 0.68 µg.ml-1.h and 2.69 ± 0.14 L.kg-1, respectively. The elimination half-life (t1/2β), total body clearance (ClB) and the ratio of drug present in peripheral to central compartment (P/C) were 5.59 ± 0.40 h, 337.6 ± 19.9 ml.kg-1.h-1 and 8.04 ± 
0.50, respectively. The present study revealed that the most suitable dosage regimen of gatifloxacin when concomitantly 
administered with meloxicam in buffalo calves would be 2.5 mg.kg-1 followed by 2.0 mg.kg-1 at 12 h intervals. 
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Resumo
Investigou-se a farmacocinética da gatifloxacina, administrada por via intravenosa, concomitante à aplicação de 
meloxicam em bezerros búfalos. O meloxicam foi administrado por via subcutânea (0,5 mg.kg-1), imediatamente seguido 
pela administração intravenosa de gatifloxacina (4 mg.kg-1). A concentração plasmática de gatifloxacina foi estimada 
por ensaio microbiológico. Os parâmetros farmacocinéticos foram calculados e a posologia adequada foi computada. 
A concentração plasmática do fármaco-terapêutico foi mantida por 12 h. A gatifloxacina foi rapidamente distribuída a 
partir de sangue para o compartimento de tecido, o que ficou evidente a partir dos valores elevados da taxa constante de 
distribuição, α1 (11.9 ± 0.52 h-1) e a proporção de velocidade constante de transferência de droga a partir de centrais para os compartimentos periféricos e vice-versa, K12/K21 (3.05 ± 0.36) e K13/K31 (2.04 ± 0.12). A área sob a curva plasmática de concentração-tempo da droga e o volume aparente de distribuição foi de 12.0 ± 0.68 μg.ml-1.h e 2.69 ± 0.14 L.kg-1, 
respectivamente. A meia-vida (t1/2β), a depuração corporal total (ClB) e relação da droga presente no sangue periférico para o compartimento central (P/C) foram 5.59 ± 0.40 h, 337.6 ± 19.9 ml.kg-1.h-1 e 8.04 ± 0.50, respectivamente. O presente 
estudo revelou que o regime de dosagem mais adequado de gatifloxacina quando administrada concomitantemente com 
meloxicam em bezerros búfalos seria 2,5 mg.kg-1 seguida de 2,0 mg.kg-1 em intervalos de 12 h.
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tions, acute pyelonephritis and gonorrhea2. Fluoro-
quinolone resistance relates directly to human and 
veterinary usage and emerging bacterial resistance 
poses the single greatest threat to the future survival 
of the fluoroquinolone drugs as an antibiotic class3. 
As a member of respiratory quinolones, gatifloxacin 
possesses enhanced activity against S. pneumoniae, H. 
influenza and M. catarrhalis4. Under field conditions, 
in the management of bacterial infections, adminis-
tration of an analgesic agent with an antibacterial is 
a regular feature. Meloxicam, a novel NSAID of the 
oxicam class, is one of the most potent inhibitors of 
cyclooxygenase-2 currently available. Fluoroquino-
lones have been known to interact with non-steroi-
dal anti inflammatory drugs at pharmacokinetic and 
pharmacodynamic level5. The pharmacokinetic study 
of gatifloxacin has been investigated in rabbits6, mice7, 
humans8 and buffalo calves9,10. Concurrent adminis-
tration of gatifloxacin has been found to alter the 
pharmacokinetics of meloxicam in buffalo calves11. 
Further, concomitant administration of meloxicam12 
and paracetamol13 have been shown to influence the 
disposition of levofloxacin in calves. However, there 
is no information available on the effect of meloxicam 
on the pharmacokinetics of gatifloxacin. In view of the 
paucity of such data on alterations in pharmacokinet-
ic behavior of simultaneously administered drugs, the 
present study was planned to determine the plasma 
levels, pharmacokinetics and an optimal dosage regi-
men of gatifloxacin in buffalo calves (Bubalus bubalis) 
after its single intravenous administration along with 
subcutaneous administration of meloxicam. 
Material and Method 
Five healthy male buffalo calves of non-descript 
breed, ranging between six months to one year of age 
and 116-168 kg body weight were used for the study. 
The animals were kept in the departmental animal 
shed under standard conditions of management for 
two weeks prior to the commencement of the study 
and were provided green fodder and water ad libitum. 
Gatifloxacin (Gatiquin, Cipla Ltd., India) was ad-
ministered at the dose rate of 4 mg.kg-1 body weight 
into the left jugular vein immediately after subcuta-
neous injection of meloxicam (Metacam, Intas Phar-
maceuticals Ltd., India) at the dose rate of 0.5 mg.kg-1 
into the neck region. The experimental protocol fol-
lowed the ethical guidelines on the proper care and 
use of animals and has been approved by the insti-
tutional animal ethics committee (Protocol Reg. no. 
497/01/a/CPCSEA). The doses of gatifloxacin and 
meloxicam employed in the present study were simi-
lar to the doses of these drugs in buffalo calves and 
calves in previous disposition studies10,12.
Heparinized blood samples (5 ml) were collected 
from the contralateral jugular vein into at 1, 2.5, 5, 
7.5, 10, 15, 30 min and 1, 2, 4, 6, 8, 10, 12, 14 and 24 
h post drug administration, as performed by previous 
workers10. Plasma was separated by centrifugation at 
1300 g for 15 min at room temperature and stored at 
-20 0C until analysis, which was performed next day. 
The concentration of gatifloxacin in plasma 
samples was estimated by a standard microbio-
logical assay technique14 using Escherichia coli 
(MTCC 739) as the test organism as per the 
method described by previous workers10. Assay 
plates were incubated at 34 0C for 12 h. At the end 
of incubation, the diameter of zone of inhibition 
of each well was measured with a Fisher Lilly An-
tibiotic Zone Reader (Fisher Scientific Company 
USA). The punching device used to create wells 
of uniform size was fabricated with six stain-
less steel columns having an inner diameter of 6 
mm fixed at equal distance to a heavy metal base 
which could be sterilized in oven. Three alternate 
wells were filled with one plasma sample and the 
remaining three wells with a reference drug solu-
tion. This method estimated the level of parent 
463
Braz. J. Vet. Res. Anim. Sci., São Paulo, v. 47,  n. 6,  p. 461-467, 2010
drug and its active metabolites having antibacte-
rial activity. The assay could detect a minimum 
of 0.05 µg.ml-1 of gatifloxacin. For each sample, 
nine replicates were analyzed and correlated with 
the zone of inhibition of standard reference so-
lution of gatifloxacin (0.2 µg.ml-1). The concen-
tration of drug in the samples was calculated as 
µg.ml-1 of plasma. 
The plasma concentration-time profile of gatifloxa-
cin after its concomitant administration with meloxi-
cam in each animal was used to establish various dis-
position kinetic determinants and the mean kinetic 
variables were obtained by averaging the variables 
calculated for individual animal. Disposition kinetic 
parameters were calculated manually by the comput-
ed least-squares linear regression technique15.
Results 
The plasma levels of gatifloxacin at different time in-
tervals following its single intravenous injection of 4 
mg.kg-1 after subcutaneous administration of meloxi-
cam (0.5 mg.kg-1) are presented in figure 1. At 1 min, 
the mean plasma drug concentration was 11.3 ± 0.45 
µg.ml-1 and the drug was detected in plasma up to 24 
h. The pharmacokinetic parameters that describe the 
distribution and elimination pattern of gatifloxacin 
were calculated and presented in table 1. Using con-
venient dosage interval, the priming (D) and mainte-
Figura 1 - Semilogarithmic plot of plasma concentration-time profile of gatifloxacin 
following its single intravenous injection of 4 mg.kg-1 body weight after 
subcutaneous administration of meloxicam (0.5 mg.kg-1) in buffalo calves. 
Values are presented as mean ± SE of five animals. The data was analyzed 
according to three-compartment open model. Distribution (α1 and α2) and elimination (b) phases are represented by least square regression 
lines. The calculated points of distribution phase were obtained by the 
feathering technique. Constants A1, A2 and B are the zero-time intercepts of distribution and elimination phases, respectively
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nance (D’) doses of gatifloxacin were calculated ac-
cording to the equations:    
D = Cp (min)    .Vd (ebt)        D’ = Cp (min)    .Vd (ebt - 1)
Where, Cp (min)     is the minimum inhibitory con-
centration of gatifloxacin, b is the elimination rate 
constant and t is the dosage interval16. Taking various 
dosage intervals for maintaining the different MICs 
ranging from 0.05 to 0.5 µg.ml-1, the priming and 
maintenance doses of gatifloxacin were calculated 
and are presented in table 2. 
Discussion and Conclusions
Evaluation of the results on observed plasma levels 
revealed that the disposition pattern of gatifloxacin 
was best fitted to three-compartment open model and 
adequately described by the tri-exponential equa-
tion Cp = A1e-α1t + A2e-α2t + Be-bt, where Cp is the 
gatifloxacin concentration at time t, A1, A2 and B are 
zero-time intercepts of distribution and elimination 
phases, respectively, α1 and α2 are the rate constants 
of distribution phases 1 and 2, respectively, b is the 
Table 1 - Pharmacokinetic parameters of intravenously administered gatifloxacin @ 4 mg.kg-1 on concomitant 
administration of meloxicam (0.5 mg.kg-1, sc) in buffalo calves (n = 5)
Parameter Unit Mean±SE
Cpo µg.ml-1 13.5 ± 0.44
A1 µg.ml-1 9.98 ± 0.39
α1 h-1 11.9 ± 0.52
t½α1 h 0.059 ± 0.003
A2 µg.ml-1 2.55 ± 0.19
α2 h-1 0.684 ± 0.05
t½α2 h 1.03 ± 0.07
B µg.ml-1 0.924 ± 0.06
b h-1 0.127 ± 0.01
t½b h 5.59 ± 0.40
AUC µg.ml-1.h 12.0 ± 0.68
AUMC µg.ml-1.h² 75.9 ± 7.50
Vdarea L.kg-1 2.69 ± 0.14
ClB ml.kg-1.h-1 337.6 ± 19.9
MRT h 6.26 ± 0.34
Kel h-1 1.13 ± 0.03
K12/K21 ratio 3.05 ± 0.36
K13/K31 ratio 2.04 ± 0.12
P/C ratio 8.04 ± 0.50
td h 24.2 ± 1.73
A1 and A2 = zero-time plasma drug concentration intercepts of the regression lines of distribution phases 1 and 2, respectively; α1 and α2 = rate constants of distribution phases 1 and 2, respectively; B and b = zero-time plasma drug concentration intercept of elimination phase and elimination rate constant, respectively; t½α1 and t½α2 = half-lives of distribution phases 1 and 2, respectively; t½b= elimination half-life; AUC = area under the plasma concentration-time curve; AUMC = area under the first moment curve; 
Vdarea= apparent volume of distribution; ClB = total body clearance; MRT = mean residence time; td = duration of therapeutic effect; K12 and K21 = micro-rate constants from central to peripheral compartment 1 and vice versa, respectively; K13 and K31 = micro-rate constants from central to peripheral compartment 2 and vice versa, respectively; Kel  = elimination rate constant from central compartment; P/C = ratio of drug present in the peripheral to central compartment
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elimination rate constant and e represents the base of 
natural logarithm. The minimum inhibitory concen-
tration (MIC90) of gatifloxacin was maintained from 
1 min to 12 h of administration. The MIC90 of gati-
floxacin against various organisms has been reported 
to be ranging from 0.015 to 8 µg.ml-1.7 In view of the 
influences of different factors in vivo and to cover ma-
jority of the susceptible microorganisms the MIC of 
gatifloxacin has been considered to be 0.2 µg.ml-1 in 
this discussion. At 1 min of injection, the peak plasma 
level was approximately 56 fold higher than the MIC 
of gatifloxacin. Gatifloxacin has been shown to attain 
plasma levels of 4.53 to 6.07 µg.ml-1 following single 
intravenous injection in human beings4,17,18. 
Gatifloxacin was rapidly transferred from the cen-
tral to peripheral compartment 1 in buffalo calves 
as is evident from the high value of distribution rate 
constant, α1 (11.9 ± 0.52 h-1). The high ratios of K12/
K21 (3.05 ± 0.36) and K13/K31 (2.04 ± 0.12) also indi-
cated rapid transfer of the drug from central to pe-
ripheral compartments. Similar trend was observed 
for the distribution of gatifloxacin into various tissues 
and body fluids after its intravenous administration 
alone in buffalo calves10. The large Vdarea (2.69 ± 0.14 
L.kg-1) and P/C ratio (8.04 ± 0.50) further suggested 
extensive penetration of gatifloxacin into the body 
fluids and tissues of buffalo calves. In accordance to 
our findings, high values of volume of distribution 
have been reported after intravenous administration 
of gatifloxacin alone in buffalo calves (3.56 L.kg-1)10 
and after single or multiple administrations of oral 
and intravenous doses of gatifloxacin in man (1.45 to 
2.01 L.kg-1)8. High value of AUC (12.0 ± 0.68 µg.ml-
1.h-1) reflected a vast area covered under drug con-
centration. In agreement to our findings, high value 
of AUC (17.1 µg.ml-1.h-1) was observed after intrave-
nous administration of gatifloxacin alone in buffalo 
calves10. High values of AUC have also been reported 
after intravenous administration of marbofloxacin 
(7.7 mg.ml-1.h) in cattle and enrofloxacin (17.8 mg.ml-1 
.h) in calves19,20.
The elimination half-life of gatifloxacin (5.59 ± 0.4 
h) calculated in the present study was shorter than 
the half life of 10.4 h obtained after administration of 
the same dose of gatifloxacin alone in buffalo calves10, 
however it was comparable to half-life reported for 
gatifloxacin (6.24 ± 9.4 h) in human beings4,17,18. Simi-
lar values have also been reported for the half-life of 
other fluoroquinolones, marbofloxacin (5.7 h) in cat-
tle20 and pefloxacin (6.88 h) in sheep21. The total body 
clearance of gatifloxacin in buffalo calves in the pres-
ent study (337.6 ± 19.9 ml.kg-1.h-1) was higher than 
the values of ClB reported after single intravenous 
injection of gatifloxacin in human beings (182-206 
ml.kg-1.h-1) and buffalo calves (235.1 ml.kg-1.h-1)10,17,22. 
This finding is supported by the earlier reports where-
Table 2 - Calculated intravenous dosage regimen of gatifloxacin at various dosage intervals, to maintain different 
therapeutic plasma drug concentrations when prescribed with meloxicam in buffalo calves
Therapeutic plasma 
concentration  
(µg. ml-1)
Dosage interval (h)
8 10 12 16 24
0.05 0.37 (0.24) 0.48 (0.35) 0.62 (0.49) 1.05 (0.92) 3.06 (2.93)
0.1 0.74 (0.47) 0.96 (0.69) 1.25 (0.98) 2.11 (1.84) 6.13 (5.86)
0.2 1.49 (0.95) 1.92 (1.39) 2.49 (1.96) 4.21 (3.67) 12.3 (11.7)
0.3 2.23 (1.42) 2.89 (2.08) 3.74 (2.93) 6.32 (5.51) 18.4 (17.6)
0.5 3.72 (2.37) 4.81 (3.46) 6.23 (4.89) 10.5 (9.18) 30.7 (29.3)
Values given are expressed as mg.kg-1 body weight; Maintenance doses are given in parentheses
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in meloxicam was reported to increase the total body 
clearance of levofloxacin two fold upon simultaneous 
administration in calves12.
The ultimate objective of the pharmacokinetic 
study was to determine an optimum intravenous 
dosage regimen of gatifloxacin. Taking 12 h as a con-
venient dosage interval, with a minimum therapeu-
tic plasma level (Cp (min)   ) of 0.2 µg.ml-1 and using 
the values of β and Vdarea from Table 1, the appro-
priate priming and maintenance dosage of gatifloxa-
cin would be 2.49 mg.kg-1 followed by 1.96 mg.kg-1 
at 12 h intervals or under field condition it would 
be 2.5 mg.kg-1 and 2.0 mg/kg-1 intravenously at 12 
h intervals, when prescribed along with meloxicam 
in buffalo calves. This dose was quite different than 
the dose of 5 mg.kg-1 at 24 h intervals calculated for 
intravenous administration of gatifloxacin alone in 
buffalo calves10.
Simultaneous administration of meloxicam in the 
present study decreased the Vdarea, P/C ratio, AUC and 
elimination half life and increased the total body clear-
ance of gatifloxacin in buffalo calves in comparison 
to gatifloxacin administered alone in buffalo calves10, 
indicating lesser distribution to peripheral tissues and 
body fluids and decreased duration of therapeutic ef-
fect of gatifloxacin when used with meloxicam. Thus 
gatifloxacin would require more frequent dosing at 
12 h intervals when prescribed along with meloxicam 
than the 24 h dosing schedule recommended for gati-
floxacin alone in buffalo calves10. 
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